India's Cipla Misses Quarterly Profit View on Muted US Sales
Muted US sales of generic Revlimid and stiff competition cut Cipla’s quarterly profit below estimates, while India revenue rose 12%, analysts said.
- On Tuesday, India's Cipla reported a 35% decline in consolidated net profit to 8.78 billion rupees for the quarter ended September 30, missing analyst estimates of 9.42 billion rupees.
- North America revenue fell 19% amid muted sales of generic Revlimid, while India business revenue rose 12%, creating a regional divergence that weighed heavily on overall performance.
- Operations revenue fell 2.4% to 74.04 billion rupees, partly due to a reclassification of marketing and promotional expenses effective April 1, 2026; the company stated this change did not impact profit.
- Following the results, Cipla shares fell as much as 2.7% to 1,319 rupees, while the broader NIPHARM index rose 1.9% in the same trading session.
- The company relies on obesity drug Yurpeak, marketed via a licensing agreement with Eli Lilly, while analysts expect Indian revenue growth to track the broader domestic pharmaceutical market.
11 Articles
11 Articles
India's Cipla misses second-quarter profit view on muted US sales
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%
Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-year decline in revenue from operations, totaling Rs 7,404 crore. Additionally, a significant 26.7% decrease in EBITDA resulted in a lower margin of 18.7%. Nonetheless, Cipla's One India division demonstrated growth across various segments, while the company aims to enhance productivity and innovate its produc…
Cipla Q2 profit falls 35 pc as North America weakness hits margins - tennews.in: National News Portal
Mumbai, Oct 27 (IANS) Pharmaceutical major Cipla on Tuesday reported a 35 per cent year-on-year (YoY) decline in its consolidated net profit for the second quarter of FY27, as weaker sales in North America and a sharp contraction in operating margins weighed on its performance. The company posted a net profit of Rs 878 crore […] The post Cipla Q2 profit falls 35 pc as North America weakness hits margins appeared first on tennews.in: National New…
Cipla Q2 Results FY27: Cons Net Profit Falls 35% to Rs 878 Crore, Misses Estimates
Noida, Oct 27 (APAC Media): Drug major Cipla on Tuesday reported a 35 per cent year-on-year decline in consolidated net profit to Rs 878 crore for the second quarter of FY27, compared with Rs 1,351 crore in the corresponding period of the previous fiscal year, the company said in a statement. The company reported total […] The post Cipla Q2 Results FY27: Cons Net Profit Falls 35% to Rs 878 Crore, Misses Estimates first appeared on APAC Media | L…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
